Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
We conducted a Phase 1b study to evaluate the immunogenicity and safety of two live attenuated tetravalent dengue vaccines in healthy adult volunteers. After one injection, all subjects reported systemic reactions consistent with a mild dengue-like syndrome. Seven volunteers developed dengue 3 viraemia after vaccination. All subjects developed a neutralizing antibody response against serotype 3 with partial response against other serotypes. The trial was stopped early (after 10 subjects enrolled) due to formulation issues, which were related to the dengue 3 vaccine component. Managing viral interference and balancing attenuation to produce acceptable tetravalent immunogenicity with minimal reactogenicity may be a recurring problem for future multivalent live vaccines.
Kitchener
Scott
S
Centre for Military and Veterans Health, Mayne Medical School, Herston, Queensland 4006, Australia. s.kitchener@uq.edu.au
Nissen
Michael
M
Nasveld
Peter
P
Forrat
Remi
R
Yoksan
Sutee
S
Lang
Jean
J
Saluzzo
Jean-François
JF
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D001315:Australia; D003715:Dengue / Q000503:physiopathology / Q000517:prevention & control*; D003716:Dengue Virus / Q000276:immunology*; D006801:Humans; D008297:Male; D008889:Military Personnel; D009500:Neutralization Tests; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D014766:Viremia
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines